Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 171, Issue 5, Pages 798-812
Publisher
Wiley
Online
2015-10-13
DOI
10.1111/bjh.13780
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma
- (2016) Xuemei Cai et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914
- (2015) Eva M. Huber et al. STRUCTURE
- Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
- (2015) S Atrash et al. Blood Cancer Journal
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib
- (2014) A Ray et al. LEUKEMIA
- Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine
- (2014) Rimda Wanchoo et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128–350 triggers MM cell death via c-Jun upregulation
- (2013) Fengjuan Fan et al. CANCER LETTERS
- Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
- (2013) A Thakurta et al. LEUKEMIA
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4
- (2012) Kwang Min Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
- (2012) P. G. Richardson et al. BLOOD
- Addiction to c-MYC in multiple myeloma
- (2012) T. Holien et al. BLOOD
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
- (2012) Kenneth C. Anderson JOURNAL OF CLINICAL ONCOLOGY
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
- (2009) D. Chauhan et al. BLOOD
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- Targeting the UPS as therapy in multiple myeloma
- (2008) Dharminder Chauhan et al. BMC BIOCHEMISTRY
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now